Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

November 18, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • FEATURED
  • COVID UPDATE: Russian Covid-19 vaccine Phase 3 trials to start in India this month, Preliminary Results by November

JNU | JRF position |DBT funded Project

BHU | Cytogenetics Laboratory Jobs| Research and Stock Curator Post

COVID UPDATE:  Russian Covid-19 vaccine Phase 3 trials to start in India this month, Preliminary Results by November
  • BiotechToday
  • FEATURED
  • India
  • Latest

COVID UPDATE: Russian Covid-19 vaccine Phase 3 trials to start in India this month, Preliminary Results by November

bioxone September 7, 2020September 7, 2020

–Sayak Biswas, Amity University Kolkata

When the world is trying to fight through the Covid-19 pandemic, Scientists and Researchers are silently working to develop vaccines which can lead to some relief. There are currently a huge number of vaccines under developed for Covid-19. One among them is the Russian vaccine Sputnik V.

The Russian vaccine was found safe in the early trials according to Lancet. It was reported that a two-stage infection develops long-lasting immunity. India, which currently holds the second position in the total coronavirus cases, is looking forward to this Russian Vaccine. Russian Direct Investment Fund’s Head Kirill Dmitriev announced that India will be conducting the Phase 3 clinical trials of the vaccine, the preliminary results of which will be available in the period of October-November. Though Sputnik V is claimed to be fast-tracked, India is looking to take a chance to stop the spread of the coronavirus. Who knows this vaccine might prove efficient enough and we get the vaccine available by the end of the year.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged corona CORONA VACCINE Covid VACCINE VACCINE IN INDIA

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Latest
  • Signaling Pathway

BHU | Cytogenetics Laboratory Jobs| Research and Stock Curator Post

bioxone September 7, 2020

–Shristi Sharma, Team bioXone BHU Cytogenetics Laboratory Jobs – Research and Stock Curator Post. Cytogenetics Laboratory at Banaras Hindu University has announced vacancies for Research Associate and Curator of Stocks position. Interested candidates may check out the details given below: Research and Stock Curator Post Applications are invited for following temporary positions available under and […]

Related Post

  • BiotechToday
  • World

Missing water molecule is the cause of Antibiotic-resistance

bioxone January 23, 2021January 23, 2021

Sristi Raj Rai, Amity University Kolkata Handicapped microbes that survive drug attacks are more dangerous than the living ones, as very soon they develop resistance to that specific drug. Macrolides, a class of broad-spectrum antibiotics that has a macrocyclic structure are produced by strains of Streptomyces. These are generally prescribed in case of bacterial infections […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Water conservation in camels aided by cholesterol!

BioTech Today July 5, 2021July 4, 2021

Komal Bavaskar, Mumbai university Camels are large animals with long legs, a large nose, and a humped back. They are divided into two types: dromedary camels with one hump and Bactrian camels with two humps. Arabian camels are also called dromedary camels are found in the Middle East & North Africa. The scientific name Camelus […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Studying p38-MAPK – A signaling pathway in mice embryos

BioTech Today July 17, 2021July 17, 2021

Agrima Bhatt, Rajasthan University In previous studies, p38-MAPK was identified as a regulator for blastocyst ICM fate in the mouse embryo. Today, scientists are trying to find out the functional role of the DDX21 protein. For the understanding of this complex pathway, let’s first deep dive into the embryo and its development stages. Fusion of […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy